The toxic mechanisms of cisplatin have been frequently studied in many species and in vitro cell models. The Netherlands Toxicogenomics Centre focuses on developing in vitro alternatives using genomics technologies for animal-based assays on, e.g. genotoxic hazards. Models such as human hepatocellular carcinoma cell line (HepG2) cells, mouse primary hepatocytes (PMH) and mouse embryonic stem cells (mESC) are used. Our aim was to identify possibly robust conserved mechanisms between these models using cisplatin as model genotoxic agent. Transcriptomic data newly generated from HepG2 cells and PMH exposed to 7 µM cisplatin for 12, 24 and 48 h and 24 and 48 h, respectively, were compared with published data from mESC exposed to 5 µM cisplatin for 2-24 h. Due to differences in response time between models and marginal changes after shorter exposure periods, we focused on 24 and 48 h. At gene level, 44 conserved differentially expressed genes (DEG), involved in processes such as apoptosis, cell cycle, DNA damage response and DNA repair, were found. Functional analysis shows that limited numbers of pathways are conserved. Transcription factor (TF) network analysis indicates 12 common TF networks responding among all models and time points. Four TF, HNF4-α, SP1, c-MYC and p53, capable of regulating ±50% of all DEG, seem of equal importance in all models and exposure periods. Here we showed that transcriptomic responses across several in vitro cell models following exposure to cisplatin are mainly determined by a conserved complex network of 4 TFs. These conserved responses are hypothesised to provide most relevant information for human toxicity prediction and may form the basis for new in vitro alternatives of risk assessment.
Introduction
Continuously, new chemicals and pharmaceuticals are being developed. All of these compounds first need to be tested for their toxic potential, such as possible genotoxic (GTX) properties, before they are allowed to enter the public market. Genotoxicity tests are routinely used for predicting some GTX properties of chemicals (1) . There are multiple in vitro genotoxicity assays available that are characterised by low specificity and as a result high false-positive rate (2) . Nowadays new tests are developed, which are aimed at being more accurate and enabling a faster toxicity testing of novel compounds. Toxicogenomics approaches, based on tools such as DNA microarrays, are used to study GTX effects of compounds by focusing on their gene expression profiles. This enables investigating mechanistic relations between these genes by studying affected molecular networks and pathways (3) . The Netherlands Toxicogenomics Centre focuses on developing better in vitro assays for assessing GTX hazards using genomics technologies. Several cell models are used for this, i.e. human hepatocellular carcinoma cell line (HepG2) cells, mouse primary hepatocytes (PMH) and mouse embryonic stem cells (mESC).
Many in vitro systems that are used for toxicity studies are derived from the liver because this is an important organ for the biotransformation of many compounds into their reactive metabolites, and thus, it is a main target for genotoxins (4) . The hepatocyte systems include among others precisioncut liver slices, primary hepatocytes and hepatoma derived, immortalised or transgenic animal-derived hepatic cell lines (5) . Primary human cells would be ideal from the perspective of human health. Donors of liver cells, however, are scarce, the degree of variability between individuals is high and the ability of differentiated cells to grow in vitro remains limited (4) . Primary hepatocytes from rodents are also frequently used, where those of mice are more metabolically stable than those of rats (6) . Alternatives for primary hepatocytes would be hepatic cell lines, such as the widely used hepatoma-derived HepG2 (7) (8) (9) (10) (11) (12) (13) (14) , BC2 (15) or the HepaRG cell line (16) . The advantage of hepatic cell lines is that they can continuously grow, have an almost unlimited life span and retain a quite stable phenotype (5) . Furthermore, there is less biological variation in these cell lines compared with primary hepatocytes. Both human HepaRG as well as HepG2 cell lines are used for genotoxicity and toxicogenomics studies (7) (8) (9) (10) (11) (12) (13) (14) 17) . Human HepaRG cells have the benefit that they are metabolically competent. HepG2 metabolic competence is less than that in human liver. HepG2 are known for their relatively low expression of cytochrome P450 enzymes; however, they are still capable of metabolizing precarcinogenic compounds as is demonstrated for instance by their capacity to form DNA adducts (7, (9) (10) (11) (12) (13) (14) . Furthermore, their value for classifying GTX compounds based on global gene expression analysis has also been shown (8) .
In addition, undifferentiated cell lines like mammalian embryonic stem cells (ESCs) are becoming more popular for genotoxicity studies (18, 19) because they are untransformed and share characteristics with cancer stem cells (20) . ESCs although not representing specific target organs such as the liver do not require immortalisation for maintaining proliferation capacity, and ESC derivatives are functional in vitro and after transplantation in vivo. Another advantage of mouse ESCs is that they can easily be genetically modified and used to generate transgenic mice (21) . Hence there is a wide range of in vitro systems available that all have their advantages and disadvantages in toxicology research.
Risk assessment assumes that there is a conserved mode of action and comparable toxic responses between species. Despite the fact that species differences exist in xenobiotic responses, e.g. due to metabolism differences, many biological systems act in an evolutionarily conserved way across a large number of species. With the use of more improved computational bioinformatic tools, microarray expression data sets may offer the opportunity to combine expression experiments from multiple species to identify genes that are not only conserved in sequence but also regulated in a similar manner across species. Orthologs are genes from different genomes that originate from a common ancestor gene by organism speciation. They are most similar by the structure of encoded proteins (compared with other genes in these genomes) and therefore should have a similar function (22) . Orthologs are used for comparative transcriptomic analyses within this study.
We therefore hypothesise that adverse response patterns conserved across in vitro models from different species including human and cell types may provide the most relevant mechanistic information for toxicity in humans. The main aim of this study is to gain insight into such conserved transcriptomic response by comparing the orthologous gene expression profiles of the three in vitro models that are used within the Netherlands Toxicogenomics Centre for developing in vitro assays for classifying GTX compounds, i.e. HepG2 cells, PMH and mESC, following exposure to a model GTX agent, namely cisplatin. The objective of our study, thus, is to investigate the robustness of the three in vitro cell models considered for 'omics-based' classification of GTX compounds and to study potential conserved response mechanisms between them. These results may help in identifying conserved responses at the level of biological and signal transduction pathways and of transcription factor (TF) networks and thereby in understanding specific modes of action of genotoxins, which in the long run could lead to better assays for human hazard identification.
The model GTX agent, cisplatin, which we here use, is a widely used chemotherapy drug for treating a variety of solid tumors, which does not require metabolic activation for exerting its GTX activity. Therefore, this compound can also be used in systems of limited metabolic competence such as mESC or HepG2 cells. The cytotoxic and GTX effects of cisplatin are a consequence of the formation of DNA adducts, especially 1,2-intrastrand d(GpG) cross-links. Cisplatin may enter the cell by passive diffusion and facilitated active transport. Spontaneous hydrolysis inside the cell results in a highly reactive metabolite, which may bind to the N7 of guanosine and adenine in the DNA, causing mutations and cell death (23) . In many tissues and cell systems, such as HepG2 (24) , cisplatin leads to inhibition of replication and transcription and to the activation of the ATM/ATR-and p53-regulated DNA damage response resulting in cell growth arrest, DNA repair and apoptosis (25) . Cisplatin is also known for its high occurrence of side effects, i.e. leading to nephro-, neuro-and ototoxicity and secondary cancers at multiple organs (25) . Hepatotoxicity has been established as one of the dose-limiting factors of cisplatin treatment (26) ; however, the mechanisms underlying this type of toxicity has not been well characterised.
In this study, cisplatin-induced transcriptomic profiles of PMH, HepG2 cells and mESC were investigated. By functional analyses of modulated biochemical pathway maps, insights into the conserved mechanisms were obtained, which provides information that could not be obtained when analyzing data from a single species. In particular, changes of TF regulatory networks were studied because they are thought to play a key role in evolution due to their direct impact on gene-expression levels (17, 27) .
Materials and methods
Cell culture and treatment HepG2. HepG2 cells were cultered as previously described by Staal and colleagues (28) . A minimally cytotoxic dose of cis-Diamineplatinum(II) dichloride (cisplatin; ≥99.9% purity, CAS no. 15663-27-1; Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands) was determined by the MTT assay (29) with 72-h exposure, resulting in ±80% viability (results are shown in supplementary Figure 1A , available at Mutagenesis Online). No further doses were investigated, as based on our previous studies in HepG2 cells we are aware that time has a much larger effect on gene expression profiles than dose (28) . Studies of cisplatin on mESC confirmed that (30) . Cell cultures were harvested at 80% confluency and seeded into 6-well plates (1.4 × 10 5 cells/well). The medium was refreshed 1 day before exposure. The HepG2 cells were exposed to 7 µM of cisplatin (the IC 20 at 72 h based on MTT assay) or to a vehicle control (0.5% of phosphate-buffered saline [PBS] ). This dose was selected because mostly death responses would be observed when choosing a higher dose. The cells were exposed for 12, 24 and 48 h in three independent experiments. These exposure periods were selected based on the fact that HepG2 cells have a cell cycle of ~20 h and would therefore respond more slowly than mESC, as the latter have a cell cycle of ~12 h.
PMH. PMH were isolated from adult male C57BL/6 mice using a perfusion method and cultured in a collagen-collagen sandwich conformation in 6-well plates as previously described (6) . After a recovery period of 40-42 h, the Dulbecco's Modified Eagle's (Gibco BRL, Breda, The Netherlands) culture medium was replaced by culture medium containing cisplatin or a vehicle control (0.5% of PBS). A minimally cytotoxic dose of cisplatin was established by the MTT assay (29) with 48-h exposure, resulting in ±80% viability (results are shown in supplementary Figure 1A , available at Mutagenesis Online). Finally, cells were treated with 7 µM cisplatin (the IC 20 at 48 h based on MTT assay) for 24 or 48 h before being harvested. Independent triplicate biological experiments with hepatocytes from different mice were obtained for every time point.
mESC. Microarray data from a previous experiment by Kruse et al. were used here (30; ArrayExpress E-TABM-89). In this experiment, wildtype mESC (cell line B4418 of C57BL/6 mice) were cultured on mouse embryonic fibroblast feeder layers by Kruse et al. (30) (Department of Toxicogenetics, LUMC, Leiden, The Netherlands). Subconfluent cultures were treated with different concentrations of cisplatin (0, 1, 2, 5 and 10 µM) for 0, 2, 4, 8 and 24 h. As measure for cytotoxicity, apoptosis was determined by annexin V/propidium iodide (AV/PI) staining. Triplicate experiments were performed for all concentrations and time-course experiments. The study from Kruse et al. again showed that time-related effects on gene expression are more pronounced than dose-related effects. The 5 µM dose at 24 hrfound in mESC causes a 20% increase in apoptosis (in comparison to exposure with the control).This would in theory be comparable with a 20% decrease in cell viability using MTT. The other doses used in this study seem to cause a lower and higher increase of apoptosis (2 µM: 10% increase of apoptosis; 10 µM: 40% increase of apoptosis) (for all apoptosis measurements, see supplementary Figure 1B , available at Mutagenesis Online). Therefore, we believe that 5 µM in mESC is the appropriate dose for comparative transcriptomics studies.
RNA isolation and quality control
At the end of the treatment, the medium was removed, and the HepG2 and PMH were harvested in Qiazol (QIAGEN Benelux B.V., Venlo, The Netherlands). Total RNA was isolated using a miRNeasy Mini Kit (QIAGEN Benelux B.V., Venlo, The Netherlands) according to the manufacturer's protocol and followed by DNase I (QIAGEN Benelux B.V., Venlo, The Netherlands) treatment. Following purification, RNA concentrations were measured by means of a NanoDrop® ND-1000 spectrophotometer (Thermo Scientific, Wilmington, USA) at 260 and 280 nm. RNA quality and integrity were assessed by using automated gel electrophoresis on an Agilent 2100 Bioanalyzer system (Agilent Technologies Netherlands B.V., Amstelveen, The Netherlands). Only RNA samples that showed clear 18S and 28S peaks and with a RNA integrity number (RIN) higher than 7.5 were used. Samples were stored at −80°C until RNA hybridisation.
Gene expression analyses using Affymetrix arrays
Labelling and hybridisation. High-density oligonucleotide GeneChips from Affymetrix (with a large number of spotted probes) were used to measure gene expression; Human Genome U133 Plus 2.0 array for HepG2 (54675 probes), Mouse Genome 430 2.0 array for PMH (45101 probes) and Mouse Genome 430A array for mESC (22621 probes). Targets for these arrays are prepared from 250 ng of total RNA by means of the GeneChip 3′ IVT Express Kit according to the Affymetrix protocol (Affymetrix UK Ltd, High Wycombe, UK). Amplified, biotinylated and fragmented targets were then hybridised on to the arrays. After hybridisation, arrays were washed and stained using an Affymetrix fluidics station and scanned by use of an Affymetrix GeneArray scanner.
A total of 18, 12 and 24 RNA samples, from HepG2, PMH and mESC, respectively, were prepared and analysed on GeneChip arrays (treated and control samples from each time point were in triplicate).
Normalisation quality controls, including scaling factors, average intensities, present calls, background intensities, noise and raw Q values, were within acceptable limits for all chips. Hybridisation controls BioB, BioC, BioD and CreX were present on all chips and yielded the expected increases in intensities. Data obtained in this study from HepG2 cells and PMH can be accessed through GEO (GSE38124).
Data analysis
Re-annotation, normalisation and data filtering. All raw data sets from generated CEL files were first imported into R2.10.1 and run through an in-house quality control pipeline (available through ArrayAnalysis.org, accessed on November 12, 2013) (31) and then used for statistical analysis. R package is freely available for academic use from the Comprehensive R Archive Network (http://www.cran.r-project.org/, accessed on November 12, 2013). After the quality control, three samples of the mESC experiments, which were control samples of 2 and 24 h and one replicate of 8 h with 5 µM cisplatin, were excluded from further analysis because they did not pass the criteria. Because two of these deviating arrays were control samples, also the matching treated samples were excluded for further analysis (11 arrays in total). For the remaining arrays, probe sets were re-annotated by use of custom Cell Definition Files (CDF) (version 13.0.0. http://brainarray.mbni.med.umich.edu/Brainarray/ Database/CustomCDF/13.0.0/entrezg.asp, accessed November 12, 2013) . This resulted in a list of 16 331, 17 726 and 12 045 unique gene IDs for PMH, HepG2 cells and mESC, respectively. After re-annotation, data were normalised by Robust Multichip Average normalisation and log 2 transformed using the R package 'affy'. Genes expressed in low levels were filtered out by using a log[intensity cut-off] > 5. This cut-off was based on the first quartile of the distribution of average intensities of all reporters. Filtering out genes expressed at low levels reduces the amount of noise being measured and thus excludes non-informative genes (32, 33) . After the genes expressed in low levels were filtered out, a list of 11 870, 13 173 and 10 705 unique gene IDs for PMH, HepG2 cells and mESC, respectively, remained for further analysis.
Selection of DEG.
After filtering, the respective log 2 ratios were calculated between the average intensities of the treated and control samples, and significance was determined by performing a paired Student's t-test using R. Absolute fold changes of 1.5 and a value of P < 0.05, unadjusted, were used for selection of DEG. No false discovery rate was used because it has been reported within the MicroArray Quality Control (MAQC) project that reproducibility of microarray data is higher when criteria such as fold change are used (34) .
Gene orthology mapping. The use of different species and microarray platforms may result in differences in gene numbers. In order to overcome this problem and to make an equal comparison between these different data sets, orthologs are used within these comparative analyses performed in this study. Orthologs are genes in different species that evolved from a common ancestral gene by speciation. Normally, orthologs retain the same function in the course of evolution. Therefore, in order to compare genes conserved across the two species, the Orthologene Library in ArrayTrack™ (35) (version 3.4.5., U.S. Food and Drug Administration, Silver Spring, USA) was used for obtaining Homologene IDs for the human and mouse arrays. The content of the Orthologene Library is mainly composed of data from the NCBI HomoloGene database. A list of 7344 Homologene IDs could be obtained (combined with human and mouse EntrezGene ID), from which the human EntrezGene IDs were used for further analyses. ArrayTrack allows rapid matching of a large number of genes across human, mouse and rat for the gene orthology analysis. The coverage of orthologs between human and mouse represented 62, 56 and 67% of the measurable genes in PMH, HepG2 and mESC, respectively. These numbers of retained orthologous genes were consistent with previous studies (36) . In the remainder part of this article, the word gene lists will refer to the orthologous gene list.
Hierarchical clustering. For HCA of the tested models and time points, a two-way method is applied by using the list of 7344 orthologue genes to investigate the grouping of samples in terms of their similarities in gene expression profiles, as well as the grouping of genes in terms of their similarities of samples. A HCA was produced using Pearson correlation, Euclidean distance with pair wise complete distance in GenePattern v.3.2.1 (http:// genepattern.broadinstitute.org, accessed on November 12, 2013).
Gene-based, pathway maps and TF analysis
To investigate the mutual gene expression changes on the single gene level, individual genes were compared between the DEG lists from all three cell models. To gain an initial insight into the function of the overlapping genes, they were categorised using the KEGG database subcategories. To further map and explore the transcriptional changes across in vitro models and to understand their biological significance into more depth, the DEG lists were further examined with MetaCore™ (GeneGo, San Diego, USA). MetaCore™ is an integrated knowledge database and software suite for pathway analysis of experimental data and gene lists. MetaCore™ is based on a proprietary manually curated database of human protein-protein, protein-DNA and protein compound interactions, metabolic and signalling pathways for human, mouse and rat, supported by proprietary ontologies and controlled vocabulary. Functional enrichment analysis was used to identify significantly modulated pathway maps. The program scores and ranks the most relevant pathway maps, which can be categorised into cellular processes. Each cellular process category contains pathway maps related to the same biological process, such as e.g. Apoptosis and Survival. In the analysis, the filtered data sets were used as background list (7344 genes). Pathway maps with a P value < 0.05 and the involvement of at least 2 genes that were significantly modulated (37) . In Metacore™, both large and small pathways are annotated, the smallest consisting of indeed no more than 2 genes. Where pathways are supposed to describe interactions between genes, it stands to reason that minimally 2 genes are required. In the analysis, a background list of the 7344 filtered genes was used. For the overlapping pathways, a common P value was calculated.
In order to explore the complexity of the transcriptional regulatory networks, TF networks were studied. The Transcription Factor Target Modeling workflow in Metacore™ was used to explore the role of TFs in the different gene sets. This workflow generates networks using the Analyze network (TF) algorithm. The algorithm looks for shortest paths from TFs to genes. The TF networks are based on literature stored within Metacore, and the direct connections between genes and TF are validated with experiments that make them trustworthy (see Metacore Manual for more information https://portal.genego.com/ help/MetaCore_Advanced_Training_Manual_5.0.pdf, accessed November 12, 2013) . TF networks with a P value < 0.05 and the involvement of at least five seed nodes were regarded as significantly involved. Per model a TF network analysis was performed, which resulted in a number of genes associated with each TF. Per model, it is then possible to extract all genes associated with these TFs. This was done for a limited set of TFs. These TF-associated genes were then compared with the total number of DEG. The genes that are related to the respective TFs were extracted and used for an additional pathway map analysis, using the total list of DEG as a background list. Also these pathway maps were divided over several cellular process categories.
Results

Effects of cisplatin at the gene level
Modulation of gene expression profiles by cisplatin in three cell models was determined by use of DNA microarrays.
Only genes measurable in all three cell models and for which human-mouse orthologues are described were taken into account. To obtain insight into the comparability of the gene expression profiles from the different models, time points and biological replicates, first a HCA was performed (supplementary Figure 2 , available at Mutagenesis Online). The clustering dendogram shows a distinction between the three models although the two liver models, PMH and HepG2, cluster together. Furthermore, the dendogram also depicts a clustering of the biological replicates.
Identification (Table I ). HepG2 cells mainly showed a high response at 24 and 48 h (898 and 1423, respectively). In mESC, however, the responses were smallest for all time points, with few DEGs at 2-4 h and more at 8 and 24 h (3, 5, 53 and 184, respectively). The overlap in responses between two models or between time points within a particular model is summarised in Table I 
Based on the limited number of gene expression changes after short incubation periods, gene expression modifications after incubation periods of the 24 and 48 h for HepG2 and PMH and 24 h for mESC were chosen for in-depth comparisons. Because mESC are rapidly replicating compared with HepG2 and PMH (the latter model does not replicate at all), we assumed that gene expression changes in HepG2 and PMH might be slower. Indeed, this agrees with the larger overlap of the 48-h data than of the 24-h data with the 24-h mESC data (Table I) . Therefore, we combined the gene expression data of both exposure periods for the liver models and compared these with the 24-h gene expression data of mESC. When analysing the DEG modulated by all models, 52 are in common between the three models (part A of Figure 1 ). For 44 of these, the change was in the same direction for all three cell models. The expression changes (presented by a heatmap) and functional annotations of the 52 common genes are provided in part B of Figure 1 . Examples of DEG fund at both time points are MDM2, PHLDA3, PPM1D, BTG2 and PERP, which are important in the regulation of apoptosis, cell cycle, cell growth and death and DNA repair. All these KEGG subcategories are related to toxic responsive processes that are frequently affected after a GTX insult. Other overlapping genes are involved in the KEGG subcategories of cell signalling or metabolism.
Effects on the 44 conserved genes by other GTX compounds
In order to further investigate whether the conservation of these found genes stretches beyond cisplatin and could also be valid for other GTX compounds, expression patterns of these 44 conserved genes were compared with data from our own group on HepG2 and PMH. For these cell models, data for several of the same GTX agents were available. With transcriptomic results from another study in HepG2 cells (8), we observed a good correlation between the expression changes after cisplatin exposure and the expression changes following exposure to several other GTX compounds (e.g. aflatoxin B1, benzo [a] pyrene, chlorambuciland and 1-ethyl-1-nitrosourea) (Table II) . Additionally, expression data from this set of conserved genes were also compared with available data on PMH exposed to a number of GTX compounds (Lizarraga et al., unpublished results), which showed an even stronger correlation (aflatoxin B1, benzo(a)pyrene, Diethylnitrosamine, 7,12-Dimethyl benzantracene and Mitomycine C) (Table II) . To further support the hypothesis that these conserved genes are also important in the human situation, we compared the average expression values from these genes with data available from primary human hepatocytes (PHH) extracted from a large database (TG-GATEs, http://toxico.nibio.go.jp/, accessed November 12, 2013) . From the GTX compounds used in HepG2 and PMH, only data on PHH treated with aflatoxin B1 and benzo[a]pyrene were present in this database. Expression patterns of PHH exposed to aflatoxin B1 showed a good correlation with our set of conserved genes as presented in Table II . Many correlations are very high, which might indicate the importance of these genes within the GTX response in other models, especially the human models.
Pathway map analysis
With functional enrichment analysis using Metacore™, significantly modulated pathway maps were identified for each model for the 24-and 48-h exposure periods, using all DEG per separate model (supplementary Table 1 , available at Mutagenesis Online). Pathway maps in which more than two genes in total were involved and of which the P value was <0.05 were considered significant. For this approach, pathway map results from 24 and 48 h were combined. Each significant pathway map was categorised according to the cellular process to which it relates. Pathways related to 'Amino acid metabolism and its regulation_Glycine, serine, cysteine and threonine metabolism' and 'Cholesterol and bile acid homeostasis_Cholesterol Biosynthesis' were identified as being present in all models as can be seen in supplementary Table 1 , available at Mutagenesis Online. Figure 2 presents a Venn diagram with the overlapping and unique pathways between the three models. For the limited set of overlapping pathways, a common P value has been calculated. Figure 3 ; supplementary Table 2 , available at Mutagenesis Online). For the two liver models, additionally AP-1, HNF1-α, E2F1, C/EBP-β and GCR-α were found, both at 24 h as well as 48 h; thus, these TFs appear tissue specific. Because we were mainly interested in the conserved response across models, we focussed on the top four of TFs that were most enriched among the modulated genes in all models and at all exposure periods, as represented by the largest number of connections (nodes) within one TF network. These were HNF4-alpha, SP1, c-MYC and p53 (see supplementary Table 2 , available at Mutagenesis Online). These four TFs together potentially regulate 911 genes (46% of the total no. of DEG) in PMH, 435 genes (48%) in HepG2 cells and 103 genes (56%) in mESC after 24-h exposure. After 48 h of exposure, 1107 genes (45%) in PMH and 710 genes (50%) in HepG2 cells were potentially regulated by these four TFs. In order to investigate the processes to be controlled by these TF networks, pathway analysis of the genes regulated by the top four TFs for the three liver models was performed. The obtained pathway maps were assigned to several cellular process categories and then compared between the models. These cellular process categories revealed a slightly stronger overlap (see Table III ) than when using all DEG for this categorisation. The cellular process categories that were significantly modulated were involved in 'Cell growth and differentiation', 'Cell cycle', 'Transcription' and 'Proteolysis' (4). In many of these pathways, a number of the same genes appear to be involved, such as Ak1, PKC, GCR-alpha, c-Jun, c-Fos and some MAPKs (such as ERK, JNK and p38 MAPK). The 'p53 signalling pathway map' and the 'Ligand-dependent activation of the ESR1/SP pathway map', both belonging to the cellular process category of 'Transcription' (presented in supplementary Figure 3 , available at Mutagenesis Online) visualises the differences and the similarities between the three cell models with respect to p53 and SP1. Additionally, the interplay between these crucial TFs in the conserved cisplatin response is further supported with a network (presented in Figure 4 ) depicting the regulation of the set of 44 conserved genes found within this study by HNF4-alpha, SP1, c-MYC and p53.
Discussion
In this study, cisplatin-induced transcriptomic profiles of PMH, HepG2 cells and mESC were investigated to gain insight into the conserved cross in vitro model responses to a direct acting DNA damaging agent. By using orthologous genes, the transcriptomic responses of all models were compared on three levels: gene, pathway maps and TF networks.
The 44 conserved genes, altered in the same direction in all three models, are involved in processes such as apoptosis, cell cycle, cell growth and death and DNA repair. Some of these genes have already been reported in the article by Kruse et al. in mESC. Furthermore, according to the Comparative Toxicogenomics Database (CTD), MDM2 (38), SERPINE2, BTG2 (39) and TAP1 (40) have been associated before with cisplatin exposure in other cell models. Some of the other genes found in this study have also been shown to be affected after exposure to other GTX chemicals such as e.g. benzo(a)pyrene and aflatoxin B1 in PMH (41) or diethylnitrosamine in mice (42) . Moreover, when comparing the expression patterns of these conserved genes, found after cisplatin exposure, with data from other studies in HepG2 and PMH, exposed to several GTX compounds, we find a strong correlation, thereby indicating the importance of these genes within the conserved response to a GTX insult. The relevance of these genes for the human situation is further supported by the fact that the expression values of these conserved genes found in this study also show a good correlation to data from PHH exposed to at least another GTX compound. From the GTX compounds used in HepG2 and PMH, unfortunately only data on PHH treated with aflatoxin B1 and benzo[a]pyrene were present in this database. However, by our approach, we were able to identify a set of genes with conserved transcriptomics responses in several mouse and human cell models, indicating that these genes are an important part of the conserved GTX response in mammalian cells. These results further substantiate that the models used are robust because the conserved genes show promising correlation with other GTX compounds and other in vitro models.
Functional analyses in MetaCore™ were performed for each model separately compared between the models. This revealed to a small extent common effects related to 'Amino acid metabolism and its regulation_Glycine, serine, cysteine and threonine metabolism' and 'Cholesterol and bile acid homeostasis_Cholesterol Biosynthesis', thus indicating a contribution of regulated metabolism-related pathways or processes, which seem to be downregulated by cisplatin. These findings are in line with a previous study performed in rat hepatocytes in which both on the genomic as well as on the proteomic levels, these processes seemed to be affected by cisplatin exposure (43) . Remarkably, we were not able to detect any effect of cisplatin exposure on common significant pathway maps related with DNA damage response. This agrees with a study in which the phosphoproteome, the proteome as well as the transcriptome were analysed in mESC after cisplatin exposure. That study suggested that the impact of cisplatin on the DNA damage response pathways was only manifested in the phosphoproteome analysis, indicating that phosphorylation events are key in activating DNA response pathways after GTX stress induced by cisplatin (18) .
Changes in TF regulatory networks were also studied, as they are thought to be conserved during evolution (27) and have been shown before to play an important role in the transcriptomic response of HepG2 cells to exposure to the GTX compound benzo[a]pyrene (17) . Comparisons based on TF networks revealed a higher degree of conservation between the models than based on analyses on gene or pathway map level. Twelve TFs were overall found to be connected to the different sets of DEG for the three models. The top four of these TFs (c-MYC, HNF4-α, p53 and SP1) are hypothesised to be responsible for up to 50% of the DEG in the different models. Three of these TFs, namely c-MYC, p53 and SP1 have been described before in literature to be involved in the cellular response to cisplatin exposure (44) . HNF4-alpha and SP1 have also been reported to play a role within the classification of compounds based on their GTX or NGTX properties using a large set of chemicals using HepG2 cells as a model (8) . In order to shed light on the possible functions of these TFs, pathway map analysis was subsequently performed with a subset of these TF regulated DEG per model separately. This indicated a strong overlap in cellular processes within these three cell models, such as cellular processes related to 'Glucocorticoid receptor signalling', 'Thrombopoietin-regulated cell processes', 'ESR1 regulation of G1/S transition', 'Influence of Ras and Rho proteins on G1/S Transition', 'p53 signalling pathway', 'Ligand-dependent activation of the ESR1/SP pathway' and 'Thrombopoietinregulated cell processes'. An overlapping subset of DEG within these categories could be observed between the models to be regulated by the same TF. However, also differences between the models remain. This indicates that the precise regulation of DEG by the same TFs can be conserved as well as cell model specific and therefore suggest that a complex network of a conserved subset of TFs is responsible for the changes in Table III . Overlapping cellular processes and significantly modulated pathway maps by TF-regulated (c-Myc, HNF4-α, p53, SP1) genes between the models and at all exposure periods genes after cisplatin exposure. In agreement with this, several genome-wide TF binding studies have shown that the patterns of some TFs can depend considerably on cell type, stage of the cell cycle or environmental conditions (45) . This cell type and differentiation state specific role of, e.g. p53 is illustrated in the visualisation of the 'p53 signalling pathway map' (depicted in supplementary Figure 3 , available at Mutagenesis Online). In this pathway map, both a subset of conserved DEG and cell model-specific DEG can be observed , which together appear responsible for the ultimate net effect for this pathway map. Here it can also be seen that the key regulators like p53 and ATM are not significantly changed in their gene expression in the in vitro models, which is in concordance with the study in mESC that showed that the DNA damage response is mainly affected at the phosphoproteome level (18) . Genes that are important in DNA damage response and actually are under control by these key regulators, such as MDM2 and p21, are indeed affected on the gene expression level in all models and at both time points. Increased levels of MDM2 would inactivate the apoptotic and cell cycle arrest functions of p53 (46) . Besides reducing p53 levels, MDM2 also promotes the expression of p21 and Rb protein, which are important regulators of cell cycle and cell death. Furthermore, MDM2 is also able to bind to SP1 and inhibits SP1-dependent transcription (47) . SP1 is a TF that influences transcription in response to physiological and pathological stimuli and regulates the expression of a large number of genes involved in a variety of processes such as cell growth, apoptosis, differentiation and immune responses. In addition, it is highly regulated by posttranslational modifications, may also have a role in modulating the cellular response to DNA damage and is implicated in chromatin remodelling (48) . Because SP1 could possibly play a crucial role in these pivotal processes in all cell models used, it seems likely that this particular TF is found to be linked with this specific conserved response.
Another TF found to be important within the conserved response is HNF4-α, which plays an essential role in the development and function organs, including hepatocytes by regulating expression of multiple genes involved in organ development, nutrient transport, and diverse metabolic pathways (e.g. cholesterol, fatty acid and glucose metabolism but also xenobiotic and drug metabolism) (49) . Furthermore HNF4-α is highly expressed in human hepatocytes (50) as well as in HepG2 cells (51) and plays a role in differentiation and functioning of the cell. In addition to its role in regulating genes responsible for differentiation and development, there is also an increasing amount of evidence suggesting that HNF4α might also play a role in regulating the cell cycle. Therefore, it seems likely that especially in the two liver models, but also in the mESC, this TF is crucial in certain processes as can be seen in Table III . Both SP1 and HNF4-α have been shown to be able to bind to promoter sites of genes involved in cell proliferation in kidney and tumor cells, respectively (52, 53) . Furthermore, SP1 seems to be regulated by p53 through multiple mechanisms (53) . Moreover, in a study with HepG2 cells (54) , overexpressed HNF4-α was found to activate the expression of p21 primarily by interacting with promoter-bound SP1.
Furthermore, MYC (c-MYC) is a TF that promotes cell growth and proliferation, and, under certain conditions, apoptosis. Additionally, it has shown to be involved in stem cell renewal (55) . Therefore, it is highly expressed in embryonic stem cells but also in human tumors. MYC is a strong proto-oncogene, and it is often found to be upregulated in many types of cancers. Levels of MYC are increased or decreased in response to mitogenic or growth-inhibitory stimuli, respectively. In addition, MYC has been shown to be a principal determinant in the crucial determination process of a cell to either undergo cell cycle arrest or apoptosis to cope with DNA damage in colon cancer cells (56) . MYC can, therefore, block p21 induction by p53 and thereby prevent transcriptional activation of this important regulator of cell cycle. The cell can then change from a cytostatic to an apoptotic fate. A study performed in HepG2 cells (54) also observed an interaction between HNF4α1 and c-MYC as well as a competition between these two TFs for interaction with promoter-bound SP1 and regulation of p21. These two TF may therefore compete for control of genes involved in cell proliferation and differentiation, which can also be hypothesised from this recent study. c-MYC was also identified as an important regulator of the transcriptomic response in HepG2 cells to benzo[a]pyrene (17) . Several studies have also proven that c-MYC can regulate and compete with a number of different TFs, including HNF-α, SP1 and p53 (57) . This may imply that all other TF described in our study might be regulated by or compete with c-MYC.
When we look at our data, we could conclude that, despite the complexity of these TF networks, we observed a common response on TF level supported by the fact that the set of conserved genes found within this study is regulated by these four crucial TFs. These findings indicate that these TFs are important in the conserved response to cisplatin in these in vitro cell models.
To further substantiate these findings at the TF level, studies on, e.g. the protein level, like the ones mentioned before (18, 43) , are needed because many TFs need post-translational modulation in order to be activated. RNA interference studies might be interesting to further explore the roles of these TF in the cisplatin-induced response. In addition, a recent study suggests that microRNAs (miR-34, 192 and 215) also play an important role in the regulation of the cisplatin-induced DNA damage response (58, 59) . C-MYC and p53 have been shown to be involved, together with specific microRNAs, in so-called feed forward loops. The interplay between TF and perhaps other post-transcriptional modifications such as microRNAs together with their regulated genes could eventually help to further define and understand the conserved cisplatin-induced genotoxicity responses between species.
More studies are needed to explore the role of these TF together with other transcriptional and post-transcriptional regulators in these type of toxic responses. Another study performed in HepG2 cells (8) already supports the finding of HNF4-alpha and SP1 to be important in the GTX response. In order to validate the findings within this study, it would furthermore be desirable to compare these results with expression values within other relevant in vitro models, such as human embryonic stem cells, following exposure to cisplatin but also in response to other GTX compounds. Furthermore, a connectivity map-based approach (60) might be a good alternative for future analysis, so this needs further attention in follow-up studies.
In summary, we conclude that we have identified transcriptomic responses conserved between hepatic/non-hepatic and differentiated/undifferentiated cell models from human and mouse origin, following exposure to the DNA damage-inducing agent cisplatin. We were able to advance beyond our previous work by demonstrating that this conservation is especially apparent on the TF networks level and also on that of genes encoding proteins. These networks are complicated and difficult to interpret. However, this study may form the basis for follow-up investigation exploring the role of these TF together with other transcriptional and post-transcriptional regulators in these types of toxic responses. Supplementary Figures 1-3 and Tables 1 and 2 are available at Mutagenesis Online.
Supplementary data
Funding
This work was supported by the Netherlands Genomics Initiative, the Netherlands Organization for Scientific Research and the Netherlands Toxicogenomic Center (grant number 050-06-510).
